Post by stocksdivas on Feb 29, 2012 14:05:36 GMT -5
ADVANCED CELL TECH (ACTC.OB)
Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company’s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company’s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Marlborough, Massachusetts.
Advanced Cell Technology Inc.
33 Locke Drive
Marlborough, MA 01752
Phone: 508-756-1212
Fax: 508-756-4468
Website: www.advancedcell.com
www.otcmarkets.com/stock/ACTC/quote
Management Team
Gary Rabin
Chairman and CEO
Gary Rabin's 24-year career in finance and operations has primarily encompassed investing in, managing and raising capital for small-cap and emerging growth companies.
From 2007 to 2010, he was Managing Partner at GR Advisors, LLC, a hedge fund focused on media and communications. From 2005 to 2007, he was a Portfolio Manager at MACInvestment Management, LLC ("MAC"), a hedge fund concentrating on technology, communications and healthcare. Prior to that he was a Managing Director and Portfolio Manager at Marketus Associates, a hedge fund focused on communications, healthcare services and energy. Before that, he was Managing Director and Co-Head of the Media and Telecom Investment Banking Group at CIBC World Markets ("CIBC"), where he was responsible for all corporate finance and M&A, financial restructurings and principal investing activities (both debt and equity) within the sector. Before joining CIBC, Mr. Rabin served as Chief Strategy Officer of CAIS Internet, Inc. ("CAIS"), a broadband services company, where he was responsible for securing over $500 million in financing commitments. Mr. Rabin has also served as Managing Director and Head of the Global Telecom Investment Banking Group at ING Barings Furman Selz and was a founder of the telecom group at UBS Securities. He began his career in finance in 1987 and concentrated on energy, utilities and metals until 1993. Mr. Rabin earned an AB in Economics from the University of Michigan.
www.advancedcell.com/company/leadership-team/senior-executive-officers/
The Company
Advanced Cell Technology, Inc., (“ACT” OTCBB: ACTC) is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.
ACT’s principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by Chairman and Chief Executive Officer Gary Rabin and Chief Scientific Officer Robert Lanza, M.D.
Therapeutic Platforms
ACT has three cellular product platforms based on ground-breaking stem cell technology. As documented in the journals Nature and Cell Stem Cell, ACT developed and holds in its repertoire the first-ever proven alternative method for successful hESC generation without harm to the embryo, called the "single-cell blastomere" technique, on which it holds broad intellectual property (IP) protection.
The company is focused on commercializing its human embryonic stem cell (hESC)-based Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease, for which it recently initiated two Phase 1/2 clinical trials.
The company is also developing its human embryonic stem cell (hESC)-based Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases. The company is developing this program in partnership with CHA Biotech of Korea.
The company is focused on advancing its Phase 2-approved Myoblast autologous adult stem cell therapy for the treatment of chronic heart failure, advanced cardiac disease, myocardial infarction, and ischemia.
Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company’s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company’s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Marlborough, Massachusetts.
Advanced Cell Technology Inc.
33 Locke Drive
Marlborough, MA 01752
Phone: 508-756-1212
Fax: 508-756-4468
Website: www.advancedcell.com
www.otcmarkets.com/stock/ACTC/quote
Management Team
Gary Rabin
Chairman and CEO
Gary Rabin's 24-year career in finance and operations has primarily encompassed investing in, managing and raising capital for small-cap and emerging growth companies.
From 2007 to 2010, he was Managing Partner at GR Advisors, LLC, a hedge fund focused on media and communications. From 2005 to 2007, he was a Portfolio Manager at MACInvestment Management, LLC ("MAC"), a hedge fund concentrating on technology, communications and healthcare. Prior to that he was a Managing Director and Portfolio Manager at Marketus Associates, a hedge fund focused on communications, healthcare services and energy. Before that, he was Managing Director and Co-Head of the Media and Telecom Investment Banking Group at CIBC World Markets ("CIBC"), where he was responsible for all corporate finance and M&A, financial restructurings and principal investing activities (both debt and equity) within the sector. Before joining CIBC, Mr. Rabin served as Chief Strategy Officer of CAIS Internet, Inc. ("CAIS"), a broadband services company, where he was responsible for securing over $500 million in financing commitments. Mr. Rabin has also served as Managing Director and Head of the Global Telecom Investment Banking Group at ING Barings Furman Selz and was a founder of the telecom group at UBS Securities. He began his career in finance in 1987 and concentrated on energy, utilities and metals until 1993. Mr. Rabin earned an AB in Economics from the University of Michigan.
www.advancedcell.com/company/leadership-team/senior-executive-officers/
The Company
Advanced Cell Technology, Inc., (“ACT” OTCBB: ACTC) is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.
ACT’s principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by Chairman and Chief Executive Officer Gary Rabin and Chief Scientific Officer Robert Lanza, M.D.
Therapeutic Platforms
ACT has three cellular product platforms based on ground-breaking stem cell technology. As documented in the journals Nature and Cell Stem Cell, ACT developed and holds in its repertoire the first-ever proven alternative method for successful hESC generation without harm to the embryo, called the "single-cell blastomere" technique, on which it holds broad intellectual property (IP) protection.
The company is focused on commercializing its human embryonic stem cell (hESC)-based Retinal Pigment Epithelial (RPE) therapy for degenerative retinal disease, for which it recently initiated two Phase 1/2 clinical trials.
The company is also developing its human embryonic stem cell (hESC)-based Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases. The company is developing this program in partnership with CHA Biotech of Korea.
The company is focused on advancing its Phase 2-approved Myoblast autologous adult stem cell therapy for the treatment of chronic heart failure, advanced cardiac disease, myocardial infarction, and ischemia.
